IP Library Granted Patent US 10,357,470
Granted Patent B2
US 10,357,470 · App. 15/652,519 · Granted Jul 23, 2019

Antimicrobial-antibiofilm compositions and methods of use thereof

Inventors: Purushottam V. Gawande (Winnipeg, CA); Karen Lovetri (Winnipeg, CA); Nandadeva Yakandawala (Winnipeg, CA); Gordon Froehlich (Selkirk, CA); Srinivasa Madhyastha (Winnipeg, CA)
Assignee: KANE BIOTECH INC.
A61K31/198A23B4/10A23B4/20A23L3/34A23L3/3463A23L3/3508A23L3/3526A23L13/50A61K31/194A61K33/30A61K45/06A23V2002/00Y02A40/943
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,357,470
App. No.
15/652,519
Granted
Jul 23, 2019
Kind
B2
Abstract

Compositions comprising chelating agents, metal ion salts, gelling agents or a buffer, antimicrobials, antibiofilm agents and a pH adjuster or a buffer for the prevention and treatment of wound infections and food-borne diseases involving bacterial biofilms are disclosed. The anti-infective properties of a composition include reduction or killing of anaerobic/aerobic/facultative gram-negative and gram-positive wound infection associated bacteria occurring in polymicrobial biofilms. The composition may be in the form of lotion, cream, ointment, dressing, bandage, rinse, soak, gel, spray, or other suitable forms, including certain devices. Additionally, the invention offers an efficient method of delivering the formulated composition containing one or two chelating agents or chelating agents alone or in combination with a metal ion salt using either a nanoparticle or other efficient delivery systems.

Claims (25)

1. A composition for inhibiting biofilm formation caused by Malassezia pachydermatis, Staphylococcus aureus , or Malassezia furfur , the composition comprising:

(a) EDTA salt at a concentration of about 0.5 mg/ml of the composition; and

(b) sodium citrate at a concentration of between about 3.2 mg/ml to about 6.4 mg/ml of the composition.

2. The composition of claim 1 , wherein the EDTA comprises disodium or tetrasodium EDTA.

3. The composition of claim 1 , comprising:

about 0.5 mg/ml EDTA salt and

about 3.2 mg/ml sodium citrate.

4. The composition of claim 1 , comprising:

about 0.5 mg/ml EDTA salt and

about 6.4 mg/ml sodium citrate.

5. The composition of claim 1 , further comprising one or more ingredients selected from the group consisting of: water, a buffer, a stabilizing agent, a gelling agent, a surfactant, a herbal, a vitamin, a mineral, an extra cellular matrix, an antimicrobial, an antibiotic, and a pH adjuster.

6. The composition of claim 1 prepared as one or more of a disinfecting solution, a dip solution, a lotion, a cream, an ointment, a gel, a spray, a dressing, a gauze, a bandage, a thermoreversible gel spray, a wrap, an adhesive, a tape, a soak, a shampoo, and a balm.

7. The composition of claim 1 , wherein the composition is delivered using a liposome or nanoparticle.

8. The composition as claimed in claim 1 , further comprising an anti-infective compound selected from the group consisting of alginate lyase, nisin, lactoferricin, serotransferrin, ovotransferrin, ovalbumin, ovomucoid, protamine sulfate, chlorhexidine, cetylpyridinium chloride, triclosan, silver sulfadiazine, benzalkonium chloride, hydrogen peroxide, citric acid, potassium citrate, 5-fuorouracil, cis-2-decenoic acid, DNase I, proteinase K, silver, gallium, bacteriocins, antimicrobial peptides and an enzyme that cleaves poly-B-1,6-N-acetylglucosamine.

9. A method of preventing or treating wound infection, comprising topical or non-topical application of the composition of claim 1 , wherein the wound infection is selected from one or more of infections of cuts, bruises, surgical sites, lacerations, abrasions, punctures, incisions, gunshots, burns, pyoderma, otitis media, otitis externa, otitis interna, cow udder mastitis, atopic dermatitis, eczema, pressure ulcers, venous and artery leg ulcers, and diabetic foot ulcers.

10. The method as set forth in claim 9 , further comprising multiple applications of the composition.

11. The method as claimed in claim 9 , wherein the method is used to treat one or more of humans, domestic animals, farm animals, zoo animals, pet animals, dogs, horses, cats, cattle, pigs, goats and sheep.

12. A method of preventing or treating meat spoilage comprising topical or non-topical use of the composition of claim 1 on meat or meat products.

13. A method of disinfecting meat comprising topical use of the composition of claim 1 on meat or meat products.

14. The method of claim 12 , wherein the meat or meat products comprises intestine or intestinal parts of pigs, cattle, sheep, goats or horses used for making sausage casings.

15. A method of preventing or treating meat spoilage comprising topical or non-topical use of the composition of claim 1 on or impregnated into collagen or cellulose for making artificial sausage casings.

16. The method of claim 12 , wherein the topical or non-topical use comprises one or more of coating, spraying, misting, injecting, soaking, flushing, dipping and rinsing.

17. A composition for inhibiting biofilm formation caused by Malassezia pachydermatis, Staphylococcus aureus ,or Malassezia furfur , the composition comprising an antimicrobial agent consisting of:

(a) EDTA salt at a concentration of about 0.5 mg/ml of the composition; and

(b) citrate salt at a concentration of between more than about 3.2 mg/ml to about 6.4 mg/ml of the composition.

Assignments (2)
SECURITY INTEREST Recorded Nov 9, 2020
From: KANE BIOTECH INC.
To: PIVOT FINANCIAL INC.
Reel/Frame 054307/0264 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 11, 2018
From: GAWANDE, PURUSHOTTAM V.; LOVETRI, KAREN; YAKANDAWALA, NANDADEVA; FROEHLICH, GORDON; MADHYASTHA, SRINIVASA
To: KANE BIOTECH INC.
Reel/Frame 044592/0307 →
Continuity (5)
Continuation In Part 14772956
Continuation In Part PCTCA2013050324 · Apr 26, 2013
Provisional Application 61834654 · Jun 13, 2013
Provisional Application 61773912 · Mar 7, 2013
Related Publication 20180015061A1 · Jan 18, 2018
Cited By (1)
US 12,251,401